Clinical trials: Brain Necrosis
Cardiovascular Complications, Hemorrhagic Disorders
Comparison of Accidents and Their Circumstances With Oral Anticoagulants
Differences in efficacy and safety between new oral anticoagulants (NOAC) and vitamin K antagonist (VKA) in real practice remain uncertain.
- Conditions
- Cardiovascular Complications, Hemorrhagic Disorders, Embolism and Thrombosis
- Trial name
- CACAO (NCT02376777)
- Testing
- Follow up
- Where
- 33 sites in France
- Volunteers
- 4,162 people
- Sponsor
- CNGE IRMG Association
Stroke, CVA (Cerebrovascular Accident)
MORbidity PRevalence Estimate In StrokE
Information regarding the likely progress of post-stroke symptoms is vitally important to stroke survivors to allow them to plan for the future and to adjust to life after stroke.
- Conditions
- Stroke, CVA (Cerebrovascular Accident), CVA; Sequelae, Stroke, Ischemic
- Trial name
- MORe PREcISE (NCT03605381)
- Where
- 3 sites in United Kingdom
- Volunteers
- 500 people
- Sponsor
- Aneurin Bevan University Health Board
Brain Diseases, Ischemic Stroke
Stroke Cerebral Reorganization Pathways (SPECTRE)
SPECTRE is a prospective longitudinal study in order to identify whether patients with different degrees of motor recovery are distinguished by distinct brain post-stroke plasticity patterns in the acute and sub-acute phases.
- Conditions
- Brain Diseases, Ischemic Stroke, Stroke, Brain Infarction
- Trial name
- SPECTRE (NCT06784518)
- Testing
- Clinical scores and functional MRI
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Rennes University Hospital
Cancer, Myocardial Infarction
NORVIT and WENBIT - Long-term Follow-up
Two large homocysteine-lowering B-vitamin intervention trials have been performed in Norway during the period 1998 to 2005, NORVIT and WENBIT.
- Conditions
- Cancer, Myocardial Infarction, Cerebrovascular Stroke
- Trial name
- NORVITWENBIT (NCT00671346)
- Where
- 2 sites in Norway
- Volunteers
- 6,839 people
- Sponsor
- Haukeland University Hospital
Ischemic Stroke, Acute
Oral DLBS1033 as Adjunctive Therapy in Acute Ischemic Stroke: Impact on Inflammatory Biomarkers and Outcomes
This randomized, double-blind, placebo-controlled trial aims to evaluate the effect of oral DLBS1033 as adjunctive therapy on inflammatory biomarkers (IL-6, TNF-α, MMP-9, D-dimer), transcranial Doppler (TCD) parameters, and…
- Trial name
- NCT07121569
- Testing
- Oral lumbrokinase DLBS1033
- Where
- Indonesia
- Volunteers
- 52 people
- Sponsor
- Universitas Sebelas Maret
Myocardial Infarction, Cardiac Arrest
Troponin-T for Detection of Perioperative Cardiovascular Events
We will conduct a prospective cohort study evaluating the incidence of and optimal risk estimation model for major perioperative cardiovascular events in consecutive patients undergoing noncardiac surgery at the 'Herlev…
- Trial name
- VISION-pilot (NCT00443989)
- Where
- 2 sites in Denmark
- Volunteers
- 100 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Intracranial Hemorrhage
Registration of Idarucizumab for Patients with IntraCranial Hemorrhage
This multicenter, prospective, observational, non-interventional study investigates patients with intracranial hemorrhage under effective anticoagulation with dabigatran or vitamin-K antagonist (VKA).
- Trial name
- RIC-ICH (NCT04062097)
- Testing
- Dabigatran Etexilate Oral Capsule [Pradaxa], Idarucizumab 2.5 GM/50 ML Intravenous Solution [PRAXBIND], Vitamin K antagonist
- Where
- 33 sites in Germany
- Volunteers
- 104 people
- Sponsor
- University Hospital, Essen
Subarachnoid Hemorrhage, Aneurysmal, Cerebrocardiac Syndrome
Mechanisms of Brain-Heart Injury of Post-Intracranial Hemorrhage
Intracranial hemorrhage is a condition characterized by high mortality rates and suboptimal functional outcomes. It precipitates both direct brain injury and subsequent secondary injuries, including delayed cerebral ischemia…
- Conditions
- Subarachnoid Hemorrhage, Aneurysmal, Cerebrocardiac Syndrome, Mass Spectrometry, Heart Failure
- Trial name
- NCT06906432
- Testing
- Multi-disciplinary assessment
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Beijing Tiantan Hospital
Death, Myocardial Infarction
A Trial Evaluating Vitamin D Normalization on Major Adverse Cardiovascular-Related Events Among Myocardial Infarction Patients
This study evaluates whether achieving 25-hydroxyvitamin D (25[OH] Vit D) levels (>40 ng/mL) among myocardial infarction patients will result in a reduction of cardiovascular-related adverse events.
- Conditions
- Death, Myocardial Infarction, Cerebral Vascular Accident, Heart Failure Hospitalization
- Trial name
- TARGET-D (NCT02996721)
- Testing
- Vitamin D3
- Where
- United States
- Volunteers
- 634 people
- Sponsor
- Intermountain Health Care, Inc.
Type 2 Diabetes and Cerebral Infarction
Effects of Glucose Fluctuation Intervention on the Prognosis of Patients With Type 2 Diabetes and Cerebral Infarction
The present randomized control trial sought to establish glucose fluctuation as an important target for management on metabolic index, neurologic function, and quality of life in Type 2 diabetes mellitus (T2DM) patients and…
- Trial name
- NCT03932084
- Testing
- Control group, Glucose fluctuation targeted intervention
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Nanjing University of Traditional Chinese Medicine
Cerebral Infarction
Early Determinants of Multidimensional Outcome at School Age After Neonatal Arterial Ischemic Stroke
While perinatal ischemic stroke is the most frequent form of childhood stroke, early determinants of outcome remain poorly understood.
- Trial name
- NCT02511249
- Where
- 5 sites in France
- Volunteers
- 80 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Diabetes Mellitus, Type 2, Acute Coronary Syndrome
Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome
The purpose of this study is to evaluate the cardiovascular outcomes of alogliptin, once daily (QD), compared with placebo, in addition to standard of care, in patients with type 2 diabetes mellitus and acute coronary syndrome.
- Trial name
- EXAMINE (NCT00968708)
- Testing
- Alogliptin
- Where
- 908 sites in United States, Argentina and 48 more
- Volunteers
- 5,380 people
- Sponsor
- Takeda
Cardiovascular Diseases, Peripheral Vascular Diseases
Homocysteine and Progression of Atherosclerosis
In the first phase, to establish the relationship of progression of peripheral vascular disease (PVD) to plasma homocysteine. In the second phase, to conduct a randomized, controlled trial of folic acid treatment of plasma…
- Conditions
- Cardiovascular Diseases, Peripheral Vascular Diseases, Atherosclerosis, Cerebrovascular Disorders
- Trial name
- NCT00005338
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Cardiovascular Diseases, Coronary Disease
Honolulu Heart Program
To investigate coronary heart disease and stroke among American men of Japanese ancestry who were living on the island of Oahu in 1965. Morbidity and mortality surveillance of the original cohort is continuing.
- Conditions
- Cardiovascular Diseases, Coronary Disease, Cerebrovascular Accident, Heart Diseases
- Trial name
- NCT00005123
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Cerebral Infarction
Overcome Biochemical Aspirin Resistance Through Cilostazol Combination
This study will recruit 316 ischemic stroke patients taking aspirin. They will be randomly assigned into cilostazol group or placebo group. Every patients will take 200mg of cilostazol a day or placebo for 1 month.
- Trial name
- ARCC (NCT00446641)
- Testing
- Cilostazol
- Where
- 4 sites in South Korea
- Volunteers
- 244 people
- Sponsor
- Asan Medical Center
Stroke, Cardiovascular
Effects of Thermal Stimulation on Motor Recovery and Neuromuscular Property of Lower Extremity in Stroke
This 3-year study will recruit a total of 72 subjects with first-ever stroke after 3 months onset from the department of Physical Medicine and Rehabilitation in 3 teaching hospitals.
- Trial name
- NCT04306120
- Testing
- Traditional Rehabilitation Therapy
- Where
- Taiwan
- Volunteers
- 37 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Carotid Stenosis, Coronary Artery Disease
Simultaneous Cardiac Surgery and Micronet-covered Stent Carotid Revascularization in High Perioperative Stroke Risk Patients
Prospective, single-center, clinical registry of patients with symptomatic/critical carotid artery stenosis at risk of stroke coexisting with unstable or multivessel severe coronary artery disease and/or severe valvular heart…
- Conditions
- Carotid Stenosis, Coronary Artery Disease, Valvular Heart Disease, Myocardial Infarction
- Trial name
- SIM-GUARD (NCT04973579)
- Testing
- Simutaneous (single anaesthesia) carotid artery stenting with MicroNet covered stent (CGuard) and cardiac surgery (CABG or surgical valve replacement / repair procedure)
- Where
- Poland
- Volunteers
- 50 people
- Sponsor
- John Paul II Hospital, Krakow
Stroke, Stroke, Acute Ischemic
NeuroAiD Patient-Reported Outcomes in Patients With Mild to Moderate Ischemic Stroke
This is a randomized, controlled, open-label study of MLC901 (NeuroAiD™ II) in patients with mild to moderate ischemic stroke. Eligible participants will be randomized in a 1:1 ratio to receive MLC901 in combination with standard…
- Conditions
- Stroke, Stroke, Acute Ischemic, Stroke, Ischemic, Stroke, Cryptogenic
- Trial name
- NAiD-PRO (NCT07828210)
- Testing
- MLC901, Standard treatment for acute ischemic stroke
- Where
- Vietnam
- Volunteers
- 80 people
- Sponsor
- EVD Pharmacy and Medical Company Limited
Radiation Necrosis
Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)
To assess the overall safety and efficacy of intra-arterial (IA) bevacizumab for the treatment of radiation necrosis. A single 2.5 mg/kg dose of bevacizumab will be given intra-arterially after osmotic blood-brain-barrier…
- Trial name
- LIBERTI (NCT02819479)
- Testing
- 25% Mannitol, Low-dose Intra-arterial Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Norton Healthcare
Cerebral Infarction
Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS)
Sarpogrelate (MCI-9042) is an antiplatelet drug that decreases 5-hydroxytryptamine (5-HT) levels in platelets via a blockade of 5-HT2 receptors; it has been used in atherosclerotic peripheral arterial disease.
- Trial name
- NCT00129805
- Testing
- MCI-9042, Aspirin
- Volunteers
- 1,510 people
- Sponsor
- Tanabe Pharma Corporation